|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,202.00 JPY | -3.72% |
|
+1.90% | +5.21% |
| 13/07 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 11/07 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,94500Cr 2.48TCr 2.15TCr 2TCr 1.84TCr 3.47TCr 2,36300Cr 3.53TCr 24TCr 9.27TCr 1,17600Cr 9.3TCr 9.09TCr | P/E 2027 * |
11.5x | P/E 2028 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3,81500Cr 2.39TCr 2.08TCr 1.94TCr 1.78TCr 3.36TCr 2,28500Cr 3.41TCr 23TCr 8.96TCr 1,13800Cr 8.99TCr 8.79TCr | EV / Sales 2027 * |
1.69x | EV / Sales 2028 * | 1.67x |
| Free-Float |
97.66% | Yield 2027 * |
3.65% | Yield 2028 * | 3.77% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -3.72% | ||
| 1 week | +1.90% | ||
| Current month | +1.24% | ||
| 1 month | +1.24% | ||
| 3 months | -1.34% | ||
| 6 months | +2.71% | ||
| Current year | +5.21% |
| 1 week | 2,166 |  | 2,305.5 |
| 1 month | 2,105 | | 2,305.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,549 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.72% | +1.90% | +47.98% | +5.87% | 2.57TCr | |
| -0.90% | -4.41% | +54.48% | +151.51% | 1,03000Cr | |
| +0.81% | -2.11% | +56.52% | +53.91% | 62TCr | |
| -2.30% | -3.06% | +33.02% | +68.09% | 45TCr | |
| +0.06% | -0.42% | +37.53% | +30.67% | 35TCr | |
| -0.14% | -0.24% | +34.41% | +39.01% | 30TCr | |
| -0.69% | -0.30% | +11.55% | +12.93% | 27TCr | |
| -7.37% | -4.40% | -2.54% | -43.87% | 23TCr | |
| -0.47% | +2.34% | +30.41% | +64.35% | 21TCr | |
| -0.57% | +0.80% | +16.07% | +71.18% | 16TCr | |
| Average | -1.48% | +4.90% | +31.94% | +45.37% | 36.38TCr | |
| Weighted average by Cap. | -0.95% | +4.88% | +39.05% | +71.84% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,26000Cr 1.42TCr 1.23TCr 1.15TCr 1.05TCr 1.99TCr 1,35400Cr 2.02TCr 14TCr 5.31TCr 67TCr 5.33TCr 5.21TCr | 2,07900Cr 1.3TCr 1.13TCr 1.06TCr 969.18Cr 1.83TCr 1,24500Cr 1.86TCr 12TCr 4.88TCr 62TCr 4.9TCr 4.79TCr |
| Net income | 34TCr 214.95Cr 186.85Cr 173.92Cr 159.68Cr 301.54Cr 21TCr 306.21Cr 2.05TCr 804.59Cr 10TCr 807.25Cr 789.52Cr | 33TCr 207.56Cr 180.43Cr 167.94Cr 154.19Cr 291.18Cr 20TCr 295.69Cr 1.98TCr 776.94Cr 9.86TCr 779.52Cr 762.39Cr |
| Net Debt | -13TCr -82Cr -71Cr -66Cr -61Cr -114.51Cr -7.79TCr -116.28Cr -778.5Cr -305.54Cr -3.88TCr -306.55Cr -299.81Cr | -47TCr -296.38Cr -257.64Cr -239.81Cr -220.18Cr -415.78Cr -28TCr -422.22Cr -2.83TCr -1.11TCr -14TCr -1.11TCr -1.09TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/26/31 | JP¥2,202.00 | -3.72% | 82,29,600 |
| 30/26/30 | JP¥2,287.00 | -0.37% | 85,31,100 |
| 29/26/29 | JP¥2,295.50 | +2.78% | 93,94,300 |
| 28/26/28 | JP¥2,233.50 | +1.06% | 70,62,100 |
| 27/26/27 | JP¥2,210.00 | +2.01% | 57,81,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
